Celldex Therapeutics (CLDX) Free Cash Flow (2010 - 2026)

Celldex Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$67.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 23.06% year-over-year to -$67.2 million; the TTM figure through Mar 2026 stood at -$226.3 million (down 30.52% YoY), while the FY2025 annual figure was -$213.7 million, down 33.79% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$67.2 million, down from -$65.2 million in the prior quarter.
• The five-year high for Free Cash Flow was -$19.2 million in Q3 2023, with the low at -$67.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$33.2 million (2024), against an average of -$38.5 million.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 46.11% in 2023, then plunged 191.81% in 2024.
• Celldex Therapeutics' Free Cash Flow stood at -$22.0 million in 2022, then tumbled by 50.93% to -$33.2 million in 2023, then decreased by 0.1% to -$33.2 million in 2024, then sank by 96.27% to -$65.2 million in 2025, then fell by 3.09% to -$67.2 million in 2026.
• Business Quant data shows CLDX's Free Cash Flow at -$67.2 million in Q1 2026, -$65.2 million in Q4 2025, and -$49.1 million in Q3 2025.